Here are the 8-K filings from Nu-Med Plus Inc (NUMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow NUMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUMD filings page.
Nu-Med Plus, Inc. (NUMD) amended its bylaws effective November 2, 2026, to require approval by a majority of votes cast by shares entitled to vote on any transfer of the company’s domicile from Utah or domestication in another jurisdiction. The vote must be at a meeting where a quorum is present, with shares represented in person or by proxy.
The 2026 annual meeting is set to be held virtually on December 14, 2026, though the company reserves the right to change the date. Shareholders of record at the close of business on November 6, 2026, are entitled to notice and to vote, and the company may change the record date. Shareholder proposals, director nominations and other business proposals must be received by close of business on November 13, 2026; proxy-inclusion proposals must also comply with applicable SEC rules, Utah law and the bylaws.
Nu-Med Plus, Inc. (NUMD) entered into subscription agreements on October 19, 2026, under which two accredited investors purchased 171,232 shares of Series A Preferred Stock for an aggregate $450,000, or $2.628 per share. Separately, the company issued an individual consultant 50,000 shares of Series A Preferred Stock for services rendered.
If converted in full and without regard to any beneficial ownership limitation, the preferred shares sold to the investors would be convertible into 3,424,640 common shares, while the consultant’s shares would be convertible into 1,000,000 common shares. The stated conversion ratio is not adjusted for a future reverse stock split. The investors received piggy-back registration rights covering common shares issuable upon conversion if the company files a resale registration statement for a secondary offering within two years after the subscription date, subject to customary requirements. The securities were unregistered; Nu-Med Plus claimed an exemption under Section 4(a)(2) and/or Rule 506 of Regulation D. No sales commissions were paid.
Nu-Med Plus, Inc. (NUMD) completed the acquisition, through its indirect wholly owned subsidiary Maritimes Gold Corp. (MGC), of a 100% beneficial interest in six gold mineral properties in Nova Scotia, New Brunswick, and Newfoundland and Labrador from MegumaGold Corp. and its subsidiaries. The properties include the Elmtree, Newfoundland, Killag, Goldenville, Miller Lake, and Caribou properties, together with associated assets.
As consideration, Nu-Med Plus issued 500,000 Series A Preferred shares to MegumaGold, granted a 5.0% net smelter returns royalty on each property to the Vendor or its subsidiaries, and MGC assumed post-transfer liabilities related to the properties and certain pre-existing royalties. Each Series A Preferred share votes and is convertible into 20 common shares, subject to beneficial ownership limitations (generally 4.999%, increaseable to 9.999% on notice). A contingent value protection feature may require Nu-Med Plus on the third anniversary measurement date to deliver additional common shares or cash if MegumaGold’s aggregate gross cash proceeds from qualifying sales of the preferred and resulting common shares are below $3.0 million, with any additional share issuance capped at 10% of Nu-Med Plus’ outstanding common stock as of that date.
Nu-Med Plus, Inc. completed the acquisition of Avid Gold Ltd, making Avid Gold and its subsidiary Maritimes Gold wholly owned in exchange for 4,500,000 shares of Series A Preferred Stock and the assumption of a $100,000 Avid Gold promissory note. Each Series A share is convertible into 20 common shares, subject to a beneficial ownership cap initially at 4.999% of outstanding common stock (electable up to 9.999%).
The company issued additional preferred equity: 225,000 Series A shares each to the Hayde Family Revocable Trust and CFO Keith Merrell, and 50,000 Series A shares to Hanover International as compensation, plus 1,000,000 Series X Super Voting Preferred shares to director and Sr. Vice President/Chief Geologist Fred Tejada. The Series X shares carry 100 votes per share.
Through the Series X issuance and a Voting Agreement with key insiders, Mr. Tejada controls voting power over 102,411,474 voting shares, or about 44.5% of the company’s approximately 230,220,035 voting shares, resulting in a change in control. The company plans to seek stockholder approval for a 1‑for‑27 reverse stock split, an increase in authorized common stock from 90,000,000 to 500,000,000, and a redomicile from Utah to Nevada. Registration rights were granted to register resales of common stock issuable from the preferred shares, and consulting agreements were entered with Mr. Hayde and Mr. Merrell. Separately, Nu‑Med and subsidiaries signed a Mineral Property Purchase Agreement to acquire six Canadian gold properties totaling over 30,900 acres, subject to closing conditions.
Nu-Med Plus, Inc. entered into a Share Exchange Agreement to acquire 100% of Avid Gold Ltd, paying 4,500,000 shares of Series A Preferred Stock and assuming a $100,000 note. Closing is subject to customary conditions and is targeted by July 8, 2026, unless extended.
After closing, Nu-Med plans a 1-for-27 reverse stock split, raising authorized common shares from 90,000,000 to 500,000,000 and potentially redomiciling from Utah to Nevada, all subject to stockholder approval. A Voting Agreement will align key holders to support these actions and Avid Gold-designated directors.
The company also signed a Mineral Property Purchase Agreement to acquire six Canadian gold properties for 500,000 Series A Preferred shares and assumed liabilities, with contingent “true-up” common shares if the vendor’s sale proceeds are below $3.0 million after three years. Nu-Med describes this strategy as diversifying into gold exploration while maintaining existing operations.